Should we be Afraid of Immune Check Point Inhibitors in Cancer Patients with Pre-Existing Rheumatic Diseases? Immunotherapy in Pre-Existing Rheumatic Diseases

Mediterranean Journal of Rheumatology

article

Kalliopi Klavdianou¹  Konstantinos Melissaropoulos²  Alexandra Filippopoulou³  Dimitrios Daoussis⁴ 

[1]Department of Rheumatology, "Asklepieion" General Hospital

[2]Department of Rheumatology, Agios Andreas Hospital

[3]Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, Hippokration General Hospital, National and Kapodistrian University of Athens

[4]Department of Rheumatology, Patras University Hospital, University of Patras Medical School

关键词: immune checkpoint inhibitors;    cancer immunotherapy pre-existing rheumatic diseases;    rheumatic diseases;   

DOI  :  10.31138/mjr.32.3.218

学科分类：社会科学、人文和艺术（综合）

来源: PCO Convin S.A.

【 摘 要 】

Background: Cancer immunotherapy is rapidly expanding but its clinical efficacy is hampered by immune related adverse events (ir-AE). There is a concern regarding patients with pre-existing autoimmune diseases (PAD) undergoing immunotherapy. Methods: An electronic search was performed (Medline) to identify cases of patients with PAD treated with immune checkpoint inhibitors (ICI). Results: Published data are rather limited but continue to emerge. Patients with PAD exhibit a high risk of PAD flare and/or de novo ir-AE. In most cases PAD flares and de novo irAEs were not severe and could be managed effectively with standard treatment. Conclusions: This risk in patients with PAD appears acceptable, and therefore, these patients could receive immunotherapy under close monitoring. Collaboration of oncologists and rheumatologists for the management of these patients is crucial.

【 授权许可】

CC BY-NC